{"disease":{"id":"recurrent-glioblastoma-multiforme-gbm","name":"recurrent glioblastoma multiforme gbm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06616727","title":"The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Shanghai Simnova Biotechnology Co.,Ltd.","has_results":false},{"nct_id":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT07497373","title":"A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Jecho Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04782609","title":"Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}